Avalo Therapeutics, Inc. (NASDAQ:AVTX – Get Rating) – Equities researchers at Jefferies Financial Group lowered their Q4 2022 EPS estimates for Avalo Therapeutics in a research note issued to investors on Monday, November 14th. Jefferies Financial Group analyst C. Howerton now expects that the company will earn ($0.55) per share for the quarter, down from their previous estimate of $0.06. The consensus estimate for Avalo Therapeutics’ current full-year earnings is ($2.66) per share. Jefferies Financial Group also issued estimates for Avalo Therapeutics’ FY2023 earnings at ($0.54) EPS, FY2024 earnings at $0.02 EPS, FY2025 earnings at ($0.14) EPS and FY2026 earnings at ($0.10) EPS.
Separately, Oppenheimer cut their price objective on shares of Avalo Therapeutics to $10.00 in a report on Tuesday.
Avalo Therapeutics Stock Performance
Institutional Investors Weigh In On Avalo Therapeutics
Hedge funds and other institutional investors have recently modified their holdings of the company. Assenagon Asset Management S.A. purchased a new position in Avalo Therapeutics during the 3rd quarter worth $52,000. Leo Brokerage LLC purchased a new stake in Avalo Therapeutics during the first quarter worth about $45,000. Goldman Sachs Group Inc. raised its position in Avalo Therapeutics by 23.8% during the second quarter. Goldman Sachs Group Inc. now owns 649,653 shares of the company’s stock worth $324,000 after acquiring an additional 124,769 shares during the last quarter. Renaissance Technologies LLC raised its position in Avalo Therapeutics by 819.1% during the first quarter. Renaissance Technologies LLC now owns 367,193 shares of the company’s stock worth $266,000 after acquiring an additional 327,241 shares during the last quarter. Finally, Millennium Management LLC acquired a new position in Avalo Therapeutics during the second quarter worth about $506,000.
About Avalo Therapeutics
Avalo Therapeutics, Inc, a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as inflammatory bowel disease, including moderate to severe Crohn's disease, and ulcerative colitis; and Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome.
- Get a free copy of the StockNews.com research report on Avalo Therapeutics (AVTX)
- Does ASML’s November Rally Have Staying Power?
- Verra Mobility Stock Has Returned Back to the Station
- Is Advance Auto Parts a Buy After its Earnings Crash?
- BJ’s Wholesale Club: Beware The Sell-Side
- The Next Catalyst For Mullen Automotive Stock Is December 23rd
Receive News & Ratings for Avalo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avalo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.